AnaptysBio, Inc. $ANAB Shares Sold by Granahan Investment Management LLC

Granahan Investment Management LLC cut its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 47.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 66,182 shares of the biotechnology company’s stock after selling 59,673 shares during the quarter. Granahan Investment Management LLC’s holdings in AnaptysBio were worth $3,670,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ANAB. Smartleaf Asset Management LLC grew its position in AnaptysBio by 5,864.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,377 shares during the period. Osaic Holdings Inc. boosted its position in shares of AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,326 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of AnaptysBio by 24.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after buying an additional 263 shares during the period.

AnaptysBio Price Performance

NASDAQ ANAB opened at $54.15 on Friday. AnaptysBio, Inc. has a 12 month low of $11.40 and a 12 month high of $72.36. The firm has a market capitalization of $1.60 billion, a PE ratio of -50.14 and a beta of 0.68. The company’s 50 day simple moving average is $58.38 and its 200 day simple moving average is $57.47.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($0.64) by ($1.20). The company had revenue of $25.56 million during the quarter, compared to analysts’ expectations of $18.86 million. Sell-side analysts anticipate that AnaptysBio, Inc. will post -1.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ANAB. Zacks Research downgraded AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings cut AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Leerink Partners set a $90.00 price target on AnaptysBio in a report on Friday, May 15th. Finally, Piper Sandler cut their price objective on shares of AnaptysBio from $95.00 to $93.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $82.00.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.